Your browser doesn't support javascript.
loading
Oxidative Stress and Neurodegeneration: Interconnected Processes in PolyQ Diseases.
Gkekas, Ioannis; Gioran, Anna; Boziki, Marina Kleopatra; Grigoriadis, Nikolaos; Chondrogianni, Niki; Petrakis, Spyros.
Afiliación
  • Gkekas I; Institute of Applied Biosciences/Centre for Research and Technology Hellas, 57001 Thessaloniki, Greece.
  • Gioran A; Institute of Chemical Biology, National Hellenic Research Foundation, 11635 Athens, Greece.
  • Boziki MK; 2nd Neurological Department, AHEPA University General Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
  • Grigoriadis N; 2nd Neurological Department, AHEPA University General Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
  • Chondrogianni N; Institute of Chemical Biology, National Hellenic Research Foundation, 11635 Athens, Greece.
  • Petrakis S; Institute of Applied Biosciences/Centre for Research and Technology Hellas, 57001 Thessaloniki, Greece.
Antioxidants (Basel) ; 10(9)2021 Sep 13.
Article en En | MEDLINE | ID: mdl-34573082
ABSTRACT
Neurodegenerative polyglutamine (polyQ) disorders are caused by trinucleotide repeat expansions within the coding region of disease-causing genes. PolyQ-expanded proteins undergo conformational changes leading to the formation of protein inclusions which are associated with selective neuronal degeneration. Several lines of evidence indicate that these mutant proteins are associated with oxidative stress, proteasome impairment and microglia activation. These events may correlate with the induction of inflammation in the nervous system and disease progression. Here, we review the effect of polyQ-induced oxidative stress in cellular and animal models of polyQ diseases. Furthermore, we discuss the interplay between oxidative stress, neurodegeneration and neuroinflammation using as an example the well-known neuroinflammatory disease, Multiple Sclerosis. Finally, we review some of the pharmaceutical interventions which may delay the onset and progression of polyQ disorders by targeting disease-associated mechanisms.
Palabras clave